Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate.
What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neut...
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.
IBB has delivered stronger returns than IYH but with dramatically sharper swings in both directions. Here is how to decide which trade-off fits your portfolio.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Eli Lilly's obesity lead is only the starting point. See what its pipeline, manufacturing build-out, pricing pressure, and earnings trajectory could mean for the stock's next chapter.
